John M. Kane (The Zucker Hillside Hospital, Glen Oaks, New York, USA Bristol-Myers Squibb, Plainsboro, New Jersey, USA Bristol-Myers Squibb, Wallingford, Connecticut, USA Otsuka America Pharmaceutical, Inc., Rockville, Maryland, USA1 The Zucker Hillside Hospital, Glen Oaks, New York, USA) Edward Kim (The Zucker Hillside Hospital, Glen Oaks, New York, USA Bristol-Myers Squibb, Plainsboro, New Jersey, USA Bristol-Myers Squibb, Wallingford, Connecticut, USA Otsuka America Pharmaceutical, Inc., Rockville, Maryland, USA2 Bristol-Myers Squibb, Plainsboro, New Jersey, USA) Hong J. Kan (The Zucker Hillside Hospital, Glen Oaks, New York, USA Bristol-Myers Squibb, Plainsboro, New Jersey, USA Bristol-Myers Squibb, Wallingford, Connecticut, USA Otsuka America Pharmaceutical, Inc., Rockville, Maryland, USA3 Bristol-Myers Squibb, Wallingford, Connecticut, USA) Zhenchao Guo (The Zucker Hillside Hospital, Glen Oaks, New York, USA Bristol-Myers Squibb, Plainsboro, New Jersey, USA Bristol-Myers Squibb, Wallingford, Connecticut, USA Otsuka America Pharmaceutical, Inc., Rockville, Maryland, USA3 Bristol-Myers Squibb, Wallingford, Connecticut, USA) John A. Bates (The Zucker Hillside Hospital, Glen Oaks, New York, USA Bristol-Myers Squibb, Plainsboro, New Jersey, USA Bristol-Myers Squibb, Wallingford, Connecticut, USA Otsuka America Pharmaceutical, Inc., Rockville, Maryland, USA2 Bristol-Myers Squibb, Plainsboro, New Jersey, USA) Richard Whitehead (The Zucker Hillside Hospital, Glen Oaks, New York, USA Bristol-Myers Squibb, Plainsboro, New Jersey, USA Bristol-Myers Squibb, Wallingford, Connecticut, USA Otsuka America Pharmaceutical, Inc., Rockville, Maryland, USA4 Otsuka America Pharmaceutical, Inc., Rockville, Maryland, USA) Andrei Pikalov (The Zucker Hillside Hospital, Glen Oaks, New York, USA Bristol-Myers Squibb, Plainsboro, New Jersey, USA Bristol-Myers Squibb, Wallingford, Connecticut, USA Otsuka America Pharmaceutical, Inc., Rockville, Maryland, USA4 Otsuka America Pharmaceutical, Inc., Rockville, Maryland, USA)
Abstract
Background: Since their introduction, second-generation antipsychotics (SGAs) have become the drugs of choice for the treatment of schizophrenia. However, recent findings have questioned the benefits of SGAs over first-generation antipsychotics (FGAs). Objective: This post hoc analysis sought to compare the utility of the SGA aripiprazole with the FGA haloperidol in patients with early-phase schizophrenia (ES) or chronic schizophrenia (CS). Method: Data were pooled from two identical 52-week, randomized, active comparator trials (31-98-217 and 31-98-304) of aripiprazole 20-30 mg/day versus haloperidol 7-10 mg/day. Patients in the efficacy sample were classified as having ES if they were ≤40 years of age with a duration of illness ≤5 years. All other patients were classified as having CS. Health-state utilities were derived from the Positive and Negative Syndrome Scale and adverse events, using the last observation carried forward method. Results: Of 1294 patients in the efficacy sample, 362 met criteria for ES (aripiprazole, n - 239; haloperidol, n - 123) and 932 met criteria for CS (aripiprazole, n - 622; haloperidol, n - 310). Baseline patient characteristics were similar between treatment arms. At week 52, patients treated with aripiprazole in the total and ES populations had significantly greater total utility than those treated with haloperidol, although there were no statistically significant differences in total utility for the CS population at week 52. For the total population, patients treated with aripiprazole had significantly higher quality-adjusted life days (QALDs)/year than haloperidol recipients (+6.48 QALDs/year, p - 0.02). Significantly higher QALDs/year were also seen for aripiprazole-treated patients with ES (+10.65 QALDs/year, p - 0.04) but not for patients with CS (+4.92 QALDs/year, p - 0.14), compared with haloperidol-treated patients. Conclusions: Aripiprazole demonstrates greater utility than haloperidol over 52 weeks of treatment. This difference was driven by superiority of aripiprazole over haloperidol in patients with ES, which was not observed in patients with CS.
Download Info
To download:
If you experience problems downloading a file, check if you have the
proper application to
view it first. Information about this may be contained
in the File-Format links below. In case of further problems read
the IDEAS help
page. Note that these files are not on the IDEAS
site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
For technical questions regarding this item, or to correct its listing, contact: (Remco Bouckaert).
Related research
Keywords:
Find related papers by JEL classification: C - Mathematical and Quantitative Methods D - Microeconomics I - Health, Education, and Welfare Z - Other Special Topics I1 - Health, Education, and Welfare - - Health I19 - Health, Education, and Welfare - - Health - - - Other I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets